Mainz Biomed (MYNZ) Issues Year-End Corporate Review
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
Mainz Biomed Provides Year-End Corporate Review 2023
January 9, 2024 8:01 AM ESTEuropean Study ColoFuture and U.S. Study eAArly DETECT report sensitivity and specificity for the detection of Colorectal Cancer and Advanced Adenoma exceeding competition
ReconAAsense designed to evaluate gold standard at-home colorectal cancer screening test and is on track to commence enrollment in mid-2024
Expanded international commercialization of ColoAlert® in major European markets and Israel
BERKELEY, Calif. and MAINZ, Germany, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:... More
